Repositioning omega-3 fatty acids for early prevention and treatment of dysglycaemia and cardiometabolic conditions

The worldwide increase in obesity, cardiovascular disease (CVD) and type 2 diabetes (T2DM) demands a greater understanding of preventive approaches and treatments, limiting the progression to poor health outcomes. With early intervention and lifestyle adjustments, early-stage metabolic disease may be slowed, stopped, and even reversed. Pharma are interested in therapies that slow or stop progression to both CVD and T2DM, and very few treatment options currently exist particularly for dysglycaemia leading to CVD. Significant advancements have been made in new medications such as GLP-1 receptor agonists (Ozempic, Wegovy and Mounjaro) to support weight loss and improve metabolic health. These treatments are most effective when combined with lifestyle modifications, however sustained drug dependency is not a preferred option for many individuals. The intersection of CVD and metabolic disorders is complex and multifaceted. A significant proportion of CVD-related deaths are intricately linked to the coexistence of metabolic conditions, particularly diabetes [1]. The metabolic alterations present in dysglycaemia (abnormal glucose levels) significantly increase the risk of CVD. A strong evidence-base exists that links CVD and dysglycaemia, with common risk factors such as elevated LDL-cholesterol, high blood pressure, obesity and smoking, reflecting the largely similar underlying drivers of atherosclerosis.